Cipla Partners Qilu Pharma for Keytruda Biosimilar in US

Cipla Limited, through its subsidiary Invagen Pharmaceuticals Inc., has entered into a strategic partnership with Qilu Pharmaceutical Co., Ltd. for the exclusive licensing and supply of QL2107, a biosimilar to Keytruda (pembrolizumab), in the United States. Qilu will handle development, regulatory registration, and supply, while Cipla USA will manage commercialization. This collaboration aims to enhance access to advanced biologic therapies for cancer patients and strengthen Cipla's oncology portfolio. The partnership leverages Qilu's development expertise and Cipla's commercial presence in the US market, with the goal of providing a high-quality, affordable pembrolizumab biosimilar.